Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | SLGC | Class A Common Stock, par value $0.0001 | 277K | Sep 1, 2021 | Direct | F1 | |||||
holding | SLGC | Class A Common Stock, par value $0.0001 | 101K | Sep 1, 2021 | See Footnote | F1, F2 | |||||
holding | SLGC | Class A Common Stock, par value $0.0001 | 12.6K | Sep 1, 2021 | See Footnote | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | SLGC | Employee Stock Option (Right to Buy) | Sep 1, 2021 | Class A Common Stock, par value $0.0001 | 21K | $4.77 | Direct | F4, F5 |
Id | Content |
---|---|
F1 | In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock. |
F2 | Reflects stock held of record by The Lillis Foundation. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares. |
F3 | Reflects stock held of record by CAG LLC. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares. |
F4 | The shares underlying the option vest in 12 equal monthly installments starting on the 1st of the first full month following the date of the grant. |
F5 | In connection with the Closing, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards. |